CEL-SCI to Present at the Fifth Annual Marcum MicroCap Conference
May 31 2016 - 8:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage cancer
immunotherapy company, announced today that it will be a featured
presenter at the 5th Annual Marcum MicroCap Conference on Thursday,
June 2, 2016 in New York City at the Grand Hyatt Hotel. The Company
presentation by Geert Kersten, Chief Executive Officer, is
scheduled to begin at 10:30 a.m. ET.
The annual Marcum MicroCap Conference is a signature showcase
for superior quality, under-followed public companies with less
than $500 million in market capitalization. For more information or
to register, please visit the conference website at
http://www.marcumllp.com/microcap.
About the Marcum MicroCap Conference
Marcum LLP is one of the largest independent public accounting
and advisory services firms in the nation, with offices in major
business markets throughout the U.S., Grand Cayman and China.
Headquartered in New York City, Marcum provides a full spectrum of
traditional tax, accounting and assurance services; advisory,
valuation and litigation support; and an extensive range of
specialty and niche industry practices. The Firm serves both
privately held and publicly traded companies, as well as high net
worth individuals, private equity and hedge funds, with a focus on
middle-market companies and closely held family businesses. In
2015, Marcum’s SEC Services Practice group led all non-“Big Four”
accounting firms in the performance of audits in connection with
Initial Public Offerings ("IPOs"). Marcum is a member of the Marcum
Group, an organization providing a comprehensive array of
professional services. For more information, visit
www.marcumllp.com.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate a
patient’s immune response to fight cancer and infectious diseases.
CEL-SCI believes that we should give the immune system the best
chance of successfully fighting cancer by administering a cancer
immunotherapy drug before surgery, radiation and chemotherapy, a
time when the immune system is thought to be strongest. The typical
cancer immunotherapy drug development path involves giving a cancer
immunotherapy after these conventional treatments.
Its lead investigational therapy, Multikine* (Leukocyte
Interleukin, Injection), is currently being studied in a pivotal
Phase 3 clinical trial as a potential neoadjuvant treatment for
patients with squamous cell carcinoma of the head and neck. Almost
800 patients were enrolled in that study at the end of April 2016.
If the study endpoint, which is a 10% improvement in overall
survival of the subjects treated with the Multikine treatment
regimen plus the current standard of care (SOC) as compared to
subjects treated with the current SOC only, is satisfied, the study
results will be used to support applications that the Company plans
to submit to regulatory agencies in order to seek commercial
marketing approvals for Multikine in major markets around the
world.
Additional clinical indications for Multikine that are being
investigated include the treatment of cervical dysplasia in HIV/HPV
co-infected women, and the treatment of peri-anal warts in HIV/HPV
co-infected men and women. A Phase 1 trial of the former indication
has been completed at the University of Maryland. The latter
indication is now in a Phase 1 trial in conjunction with the U.S.
Naval Medical Center, San Diego, under a CRADA and UCSF.
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand
Epitope Antigen Presentation System) technology as a potential
vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in CEL-SCI
Corporation's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K for the year
ended September 30, 2015. The Company undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
*Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy have not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is currently in
progress.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160531005148/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2024 to May 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From May 2023 to May 2024